SOPHiA GENETICS: The Backlog Finally Became Revenue — and 2027 Is Already 95% Spoken For
A 25% grower that spent years signing customers before billing them is now converting, while BioPharma flips from apology to accelerator — but the gross-margin footnote and a quietly de-emphasized keyword complicate the story.
SOPH · Earnings Call · 2026-11-03
The backlog finally became the revenue
For several years SOPHiA GENETICS sold a narrative about a signed-but-not-yet-billing customer base — a backlog of land wins waiting to be implemented and turned into usage-based revenue. Q3 2026 is the quarter that story started printing as numbers rather than promises. Revenue landed at $24.3 million, up 25% year over year (26% constant currency), platform analyses hit a record 118,000 (up 19%), and the company reminded investors that net dollar retention had climbed to 118% — up 950 basis points from 108% a year earlier — on annualized churn "under 1%," genuinely software-grade stickiness. The scale is no longer abstract: “we analyzed roughly 40,000 patients per month across a network that spans 75 countries and 551 connected institutions globally.” — Ross Muken, Chief Executive Officer · 2026-11-03 The company's own core genomic customer count rose to 551 from 488, even though a customer must run on the platform for a year before it counts — meaning today's number systematically lags today's signings. That lag is the whole investment case, and CFO George Cardoza quantified it with unusual bluntness:
when you look at our 2027 numbers, 95% of that growth is basically already covered or signed up... the revenue growth that you're going to see in 2027, it's from the closes that we've made in 2026.
A 95% pre-sold growth year is a rare thing for a $588 million market-cap company to claim, and it reframes SOPHiA from "growth story that keeps promising" to "growth story with unusually visible conversion."
BioPharma stops being the apology
For most of the prior stretch, BioPharma was the drag management had to explain away. On the Nov 2025 call, Cardoza conceded that “there was a fairly small amount of pharma in Q3, and we had said that last quarter that pharma was really going to ramp up in the fourth quarter.” — George Cardoza, Chief Financial Officer · 2025-11-04 A year later the framing has inverted: BioPharma is now described as an accelerator to the growth rate. This quarter added a top-10 BioPharma collaboration to build a multimodal AI predictor for which patients benefit from immunotherapy, on top of the two AstraZeneca companion-diagnostic programs (prostate and blood cancer). The interesting cross-read is that SOPHiA's new predictor is squarely in bladder cancer — and AstraZeneca, SOPHiA's own CDx partner, spent its 2026-11-03 call describing an "immunotherapy backbone across bladder cancer." This isn't a random adjacency; SOPHiA's BioPharma deal sits inside a live, actively narrated pharma conversation about exactly that indication. That is what genuine thematic confluence looks like versus a company simply borrowing a hot word. The mechanism management keeps selling is the flywheel: a diagnostic built on a decentralized network launches "where oncologists are already working," rather than depending on shipping samples to one central lab.
The margin footnote management would rather you skip
The blemish is gross margin, which fell year over year — 65.7% versus 66.3%, adjusted 72.8% versus 73.1% — even as the prepared remarks emphasized a "highly scalable" platform. That is not a contradiction per se, but it reframes where the celebrated ~60% incremental-revenue flow-through actually comes from: the operating-expense line (R&D down 18%, G&A roughly flat), not improving unit economics. Cardoza already pre-flagged the culprit on the prior call: “We do have some pharma business. And if anything could be lumpy on the margin side, it would probably be more of the pharma business.” — George Cardoza, Chief Financial Officer · 2026-05-05 As BioPharma ramps, front-loaded project and companion-diagnostic costs weigh on margins before revenue catches up. The CFO's answer to the analyst probing this was directionally reassuring — “if you think of our revenue doubling, that incremental revenue actually will come in at higher margins than what we see currently” — George Cardoza, Chief Financial Officer · 2026-11-03 — but it remains a promise, not a printed number. So the real profitability engine today is cost discipline plus mix, not leverage in the classic sense.
What management stopped saying
There is a quiet tell in the language. Liquid biopsy was once the marquee narrative keyword; it has since slipped well down the company's keyword hierarchy — exactly as the business finally inflects, with “4,200 Liquid Biopsy analysis globally, up more than 100% year-on-year and 41% sequentially versus Q2 levels.” — Ross Muken, Chief Executive Officer · 2026-11-03 The story caught up to the marketing, so it no longer needs to lead. The flip side is clinical intelligence — the CEO's new central framing — which actually lost top-billing in the curated keyword set this quarter even as Ross Muken repeats it relentlessly. That is a repositioning from "AI platform" toward "intelligence layer for health care," a deliberate bid to be valued as data infrastructure rather than a diagnostics tool. It also shows up in the new medical affairs function aimed at building evidence and reimbursement abroad. The ex U.S. push is the swing factor here — the U.S. grew 45% and now leads, but Africa-Europe and Asia are where the Solid Tumor and MSK IMPACT Flex products must prove they travel. Latin America, called out as "disappointed" as recently as the May 2026 call — “we've been disappointed in that region... Brazil at the moment is where some of that softness is kind of isolated” — Ross Muken, Company President · 2026-05-05 — now reads as "strong growth in Brazil and Colombia," a clean reversal worth watching for durability.
The durability question
The setup is genuinely favorable: $94 million in cash, a reaffirmed plan to cross to positive adjusted EBITDA in the second half of 2027, and full-year guidance nudged to the top of the $94–96 million range despite an FX headwind from a stronger euro and franc. The Guardant legal overhang is fading — the Paris court confirmed no injunction and that SOPHiA can commercialize MSK-ACCESS without restriction, with only U.K. claims lingering and a modest $931,000 in net legal expense this quarter. The bear case is not the demand picture (bookings were called one of the best ever, with both clinical and BioPharma pipelines above $100 million); it is whether implementation velocity can keep pace so that a 95%-covered 2027 converts on schedule, and whether BioPharma margin lumpiness delays the profitability crossing. That is a far better problem than the one SOPHiA had two years ago — but it is a problem nonetheless, and it is the one to monitor.